Latest / Pharmacy Podcast Network / Navigating the Next Wave: CEO Insights on Pharma’s Future | Executive Dose
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:29Speaker 1: Welcome to Executive Dose, the podcast where pharmaceutical leadership meets
- 0:35Speaker 1: unfiltered insight. Hosted by Stephen Beckman, CEO of Your All Pharma,
- 0:40Speaker 1: Each episode explores the complex forces shaping today's pharmaceutical industry,
- 0:44Speaker 1: from global supply chain stress and regulatory shakeups to innovation
- 0:48Speaker 1: in branded and generic drug markets. Join us as we
- 0:51Speaker 1: engage sea level leaders and decision makers in candid conversations
- 0:55Speaker 1: about navigating disruption, driving growth, and preparing for the next
- 0:59Speaker 1: era of pharmaceutical transformation. Curiosity leads, strategy follows. This is
- 1:04Speaker 1: the Executive Dose.
- 1:09Speaker 2: Hey, this is a special episode. This is the new podcast.
- 1:13Speaker 2: If you read the press release, I was very excited
- 1:15Speaker 2: to announce this. We have a we have a podcast
- 1:20Speaker 2: that I've been wanting to do for quite some time.
- 1:22Speaker 2: And you can't do these unless you really have people
- 1:25Speaker 2: that can backfill the intelligence that's necessary to pull it off.
- 1:29Speaker 2: That's why people like Jenna Quinn with the Pediatric Pharmacist
- 1:32Speaker 2: Review is Perfect and Tamara Arugals and the team at
- 1:37Speaker 2: the Pain Pod with Mark Gerrol Foley. So when we
- 1:41Speaker 2: look to insights when we're trying to build a show
- 1:43Speaker 2: all about the pharmaceutical leadership issues that that ecosystem is
- 1:48Speaker 2: part of our environment as healthcare providers and pharmacists out
- 1:52Speaker 2: there linking them together. The Executive Dose is a brand
- 1:56Speaker 2: new podcast part of the Pharmacy Podcast Network, and i'd
- 1:59Speaker 2: like to welcome our host to the show, Steven Beckman.
- 2:04Speaker 3: Well, it's a pleasure to be here, Todd. It's a
- 2:06Speaker 3: long time in coming. I think not only did you
- 2:09Speaker 3: want to do this, but I think this is something
- 2:11Speaker 3: that I felt compelled to do, being in the industry
- 2:14Speaker 3: for a long time and knowing that we have to
- 2:16Speaker 3: continue to do things better.
- 2:17Speaker 2: Yeah, and I really appreciate it because this takes up
- 2:20Speaker 2: a lot of time. People that do anything right back
- 2:24Speaker 2: when I was blogging a blog was taking me research,
- 2:27Speaker 2: It was taking me follow up if I had quotes
- 2:30Speaker 2: from people that were involved in it. There's a lot
- 2:32Speaker 2: of staging. So the whole purpose of what we do
- 2:36Speaker 2: at the PPN is surround you with all of the
- 2:40Speaker 2: administration and this kind of recording in the marketing and
- 2:43Speaker 2: the leveraging, and then taking your voice and some of
- 2:47Speaker 2: your ideas and started connecting them to our listeners and
- 2:50Speaker 2: get listeners to start feeding back to us what we
- 2:53Speaker 2: might be missing. So a shout out to our listeners
- 2:57Speaker 2: and understanding what the executive dose is really about. I'm
- 3:01Speaker 2: going to ask you, Steven, though, from your perspective as
- 3:04Speaker 2: our host, what is the executive dose about?
- 3:08Speaker 3: Well, you know, I think when we really think to
- 3:10Speaker 3: your point about the ecosystem and healthcare, it really is
- 3:14Speaker 3: all interdependent. You know. It starts with on our side
- 3:19Speaker 3: of things with API and developing drugs and approving drugs
- 3:22Speaker 3: and then making them available. On the delivery side or
- 3:25Speaker 3: the professional health care side, it's managing those patients, diagnosing, treating, supporting.
- 3:32Speaker 3: But it all has to come together, and ultimately we're
- 3:35Speaker 3: all linked because you know, we provide the products that
- 3:38Speaker 3: the physicians determine are appropriate for patients. They have to
- 3:41Speaker 3: go through the system and ultimately down to the pharmacist,
- 3:44Speaker 3: and the pharmacist has to be able to deliver that
- 3:47Speaker 3: medicine to the patients and also be that advocate for
- 3:51Speaker 3: them and a go betwe between doctors sometimes and so forth.
- 3:54Speaker 3: So when you really think about it, you know the
- 3:57Speaker 3: things that are impacting us on the manufacturing side or
- 3:59Speaker 3: the pharmaceutical side can trickle down through that ecosystem or
- 4:03Speaker 3: through that interdependency. So I think one of the things
- 4:06Speaker 3: that we want to bring light to is we want
- 4:09Speaker 3: to bring a bunch of different people on to talk
- 4:12Speaker 3: about the topics that affect us all. But I don't
- 4:15Speaker 3: think everybody knows why they affect us or how it
- 4:17Speaker 3: affects us. How does it affect the manufacturer, different from
- 4:20Speaker 3: a provider, from a payer, from a pharmacist, and then
- 4:24Speaker 3: ultimately the patient. So for me, it was about raising
- 4:28Speaker 3: the awareness and getting everybody a little bit closer to
- 4:32Speaker 3: each other. You know, we're not this big, bad pharmaceutical
- 4:35Speaker 3: industry or we're not this or that or so we
- 4:39Speaker 3: want pharmacists in particular, through this platform, to understand some
- 4:43Speaker 3: of the critical thinking and some of the challenges both
- 4:46Speaker 3: that might be happening internally within our organizations or the
- 4:49Speaker 3: outside pressures that are impacting us. And how's that all
- 4:53Speaker 3: ultimately flowed down With the goal then maybe through this
- 4:57Speaker 3: kind of dialogue, we'll have a greater appreciation for every
- 5:00Speaker 3: bodies needs, issues and challenges, and from that we can
- 5:03Speaker 3: find some solutions. And it starts maybe with just a
- 5:05Speaker 3: basic better understanding or basic understanding of some of the things,
- 5:09Speaker 3: because I'm sure there's a lot of misperceptions. I know
- 5:11Speaker 3: there's a lot of misperceptions that we have sometimes of
- 5:13Speaker 3: our customers and how things work or what things are
- 5:16Speaker 3: really impacting them. And I want to learn, and I
- 5:21Speaker 3: want our organization and other organizations to be able to
- 5:25Speaker 3: learn and use that institutional knowledge better than we are today.
- 5:30Speaker 3: So hopefully what executive does will be about it will
- 5:32Speaker 3: be a dialogue that will open up between manufacturers all
- 5:36Speaker 3: the way down to the pharmacist, and in that dialogue
- 5:39Speaker 3: and insight will all be in a better place. We'll
- 5:41Speaker 3: all be more creative, we'll all have a greater appreciation
- 5:44Speaker 3: for the strengths and challenges and together will work better.
- 5:48Speaker 3: And ultimately that's what we want to do, you know,
- 5:50Speaker 3: in our organization at your RAL, one of the things
- 5:52Speaker 3: that we have made a primary focus of what we
- 5:55Speaker 3: do is really the pharmacy channel, and for the last year,
- 5:59Speaker 3: obviously working with you and other things that we've been doing,
- 6:02Speaker 3: is to really make sure that the pharmacy channel understands
- 6:05Speaker 3: as a manufacturing organization providing these products down through the
- 6:08Speaker 3: system is that we want to do a better job,
- 6:11Speaker 3: and that starts with listening and dialoguing, identifying the things
- 6:16Speaker 3: that we want to work on, and then through that
- 6:18Speaker 3: we can do it in a collaborative way. And I
- 6:21Speaker 3: always believe if you can do it in a collaborative way,
- 6:23Speaker 3: you're going to end up in a better, better outcome.
- 6:26Speaker 3: You know, I tell my team. They probably hear this
- 6:29Speaker 3: every week, but I always tell them that individuals can
- 6:32Speaker 3: do great things, but teams can do exceptional things. You
- 6:35Speaker 3: have to work at it right. And I believe that
- 6:38Speaker 3: ultimately the team is all of us, from provider to pharmacists,
- 6:43Speaker 3: to patient, to a payer, to PBMs to manufacturers, we're
- 6:47Speaker 3: all actually on the same team because we're all trying
- 6:50Speaker 3: to deliver quality outcome to the patients that need it.
- 6:53Speaker 3: Whether it be treatments, so whether it be a drug treatment,
- 6:57Speaker 3: whether it be mental health, anything that encompasses That's what
- 7:02Speaker 3: we want to do, is that we want to make
- 7:04Speaker 3: the outcome for the patient better. And we use that
- 7:07Speaker 3: a lot in our company, and maybe a lot of
- 7:09Speaker 3: pharmacists and other people in the ecosystem don't think that
- 7:12Speaker 3: we talk that way, but we do. We talk a
- 7:15Speaker 3: lot about as manufacturers not just selling product, but we
- 7:20Speaker 3: talk about how our product is really driving better outcome.
- 7:24Speaker 3: So with physicians we talk about the therapeutic outimes, outcomes
- 7:28Speaker 3: in terms of accessibility of products. All those things come
- 7:31Speaker 3: in and I want to do a better job. Our
- 7:33Speaker 3: organization wants to do a better job. Hopefully through all
- 7:35Speaker 3: the people we talk to, everybody can end up doing
- 7:38Speaker 3: something a little bit better tomorrow than we're doing today. Yea.
- 7:42Speaker 2: I love the conversations that you already had. I love
- 7:45Speaker 2: listening to you and Mark Gari Foley talk about pain
- 7:48Speaker 2: management and how that applies to the care that pharmacists give.
- 7:52Speaker 2: And we're going to get into senior care. We're going
- 7:54Speaker 2: to have a special series on sports pharmacy, which is
- 7:57Speaker 2: just money. It's exploding, and the ability to drive change
- 8:04Speaker 2: at the collegiate level of athletics or the professional level,
- 8:08Speaker 2: or some high school community getting more care from a pharmacist,
- 8:13Speaker 2: a pharmacist that's probably in their community, but they have
- 8:17Speaker 2: no idea that the pharmacist is capable of it. How
- 8:19Speaker 2: did you get started in this because I kind of
- 8:22Speaker 2: want to shift for the listener's perspective. You know a
- 8:25Speaker 2: little bit about who is Steve Beckman.
- 8:27Speaker 3: Well, I've been in the industry for more years than
- 8:30Speaker 3: I can account. I actually started in the industry back
- 8:34Speaker 3: right out of undergrad and funny enough, I interviewed with
- 8:38Speaker 3: any company that would come to campus. I'm a proud
- 8:42Speaker 3: graduate of Syracuse University undergrad, so go Orange for all
- 8:45Speaker 3: those people that might be listened one day that are
- 8:49Speaker 3: are Orange men or maybe a future Orangeman. And I
- 8:53Speaker 3: ended up with seven of job offers from Coca Cola
- 8:57Speaker 3: to Armstrong World Industries, which is flow to It's a
- 9:01Speaker 3: Chicago Tribune where I helped put myself through school working
- 9:04Speaker 3: at the Syracuse newspapers. And then I also had a
- 9:06Speaker 3: couple offers from merk and Key Pharmaceucals back in the day.
- 9:12Speaker 3: That company has been absorbed through many companies. And I
- 9:16Speaker 3: sat down one night and I said, you know, I
- 9:18Speaker 3: don't come with a science background, but I have my
- 9:21Speaker 3: opportunity to sell syrup or sugar to people. I can
- 9:24Speaker 3: sell flooring, or maybe I could do something really good
- 9:28Speaker 3: through working in the pharmaceutical industry and helping patients. So
- 9:32Speaker 3: a good friend of mine, actually a former a college
- 9:36Speaker 3: made of mine, who was in the industry said it
- 9:38Speaker 3: was very simple. Either you'll get it or you won't.
- 9:41Speaker 3: And so I said, okay, that makes sense. So I
- 9:44Speaker 3: picked a job in the industry and I've been doing
- 9:47Speaker 3: it for over thirty years. So I guess I got it.
- 9:50Speaker 2: You did, you got it. So that's just a preface
- 9:54Speaker 2: to the executive does with how how you have had
- 9:58Speaker 2: changing experience is from one level to the next. And
- 10:02Speaker 2: now we have an opportunity to talk with your boss
- 10:07Speaker 2: and bringing his insights into the executive dose, and that's
- 10:12Speaker 2: going to continue. I'm thinking of other leaders, I'm thinking
- 10:17Speaker 2: of politicians. I'm thinking of artificial intelligence and special guests
- 10:22Speaker 2: like we've heard John Nassa you know, will be on.
- 10:25Speaker 2: And so I think this is a very unique podcast
- 10:29Speaker 2: and I think the listeners don't really get especially in
- 10:33Speaker 2: this in the on the network that we're on, Pharmacy
- 10:36Speaker 2: Podcast Network, We've had never had a podcast like this.
- 10:39Speaker 2: So this is a this is an educational piece for us.
- 10:42Speaker 2: Think about this four thousand episodes and sixteen years, the
- 10:46Speaker 2: books that I could write from all of the excellence
- 10:48Speaker 2: that I've I've interviewed the people. You people out there,
- 10:52Speaker 2: that's right, I just said, you people out there that
- 10:54Speaker 2: are just you know, in the pharmaceutical landscape, in the
- 10:57Speaker 2: pharmaceutical ecosystem, and so yeah, this.
- 11:01Speaker 3: Yeah, I think, you know, one of the great things
- 11:03Speaker 3: is obviously we've identified a number of topics that we
- 11:06Speaker 3: like to tackle, and we have a unique group of
- 11:09Speaker 3: people that are starting to formulate that are planning to
- 11:11Speaker 3: be guests against some of those topics. But I think
- 11:13Speaker 3: the other thing which will be great is that as
- 11:15Speaker 3: some listeners that you have developed and are in your network,
- 11:19Speaker 3: we encourage them to reach out and let us know
- 11:21Speaker 3: what topics are important to them. You know, again, as
- 11:24Speaker 3: I was saying, you know, we do we spend a
- 11:28Speaker 3: lot of money doing market research, qualitative, quantitative, We talk,
- 11:32Speaker 3: then we do advisories, but a lot of times we
- 11:35Speaker 3: still we think in that isolation. We take the information,
- 11:39Speaker 3: but then we we go and synthesize and determine what
- 11:42Speaker 3: we think is the answer. What we want to try
- 11:44Speaker 3: to do here is to to raise the outcome for everybody.
- 11:48Speaker 3: And when I say outcome, you know, it always starts
- 11:50Speaker 3: and ends with the patient outcome. That we want to
- 11:52Speaker 3: make patients better, but we also have to make sure
- 11:56Speaker 3: that the system has a healthy outcome, meaning pharmacists have
- 12:00Speaker 3: to be able to be successful. And you know, in
- 12:03Speaker 3: this world we do not have nonprofit pharmacies, so we
- 12:06Speaker 3: do need to make pharmacies profitable. We need to make
- 12:09Speaker 3: the system work for everybody in it. We need to
- 12:12Speaker 3: make it work for physicians, for pharmacists, for manufacturers, and
- 12:15Speaker 3: everybody in between. So you know, there's a lot of
- 12:18Speaker 3: topics that some are very broad in universal so maybe
- 12:22Speaker 3: more specific. But I think what we want to try
- 12:24Speaker 3: to do is is dissect some of these topics in
- 12:29Speaker 3: a way that everybody can have a deeper appreciation of
- 12:32Speaker 3: how we're looking at them from the different angles, from
- 12:34Speaker 3: the manufacturer side down. And again, as I said, when
- 12:37Speaker 3: we do that, I think that conversation is going to
- 12:39Speaker 3: open the eyes to an AHA or maybe if nothing else,
- 12:44Speaker 3: very simply an appreciation for each other to the point
- 12:47Speaker 3: that we can work better than we are today. And
- 12:50Speaker 3: I think that's really important.
- 12:52Speaker 2: I thought about you at the ASSEMBIA conference because we
- 12:55Speaker 2: were talking about gene cell therapy and biosimilars. That is
- 13:00Speaker 2: one of the topics that will be digging into a
- 13:03Speaker 2: shout out to the market. If you're listening and and
- 13:06Speaker 2: you have interest, or you know, if someone in in
- 13:09Speaker 2: that realm. We're going to be really rounding out that
- 13:13Speaker 2: subject because it's going to be a big it's going
- 13:15Speaker 2: to be a big impact in a lot of disease
- 13:16Speaker 2: state management.
- 13:17Speaker 3: Yeah, there's no doubt there's huge topics out there now.
- 13:20Speaker 3: They're impacting us obviously, everything from our new federal government
- 13:24Speaker 3: and their approach to tariffs to pricing equality across the markets. Now,
- 13:31Speaker 3: obviously that's a big pressure. You know, there's even topics
- 13:35Speaker 3: that are as simple as you know. I don't know
- 13:37Speaker 3: if most people understand, but over ninety percent of all
- 13:40Speaker 3: the API or the pharmacal drug product is produced outside
- 13:45Speaker 3: the US, most of the manufacturings outside of the US.
- 13:49Speaker 3: How do we create better stability in all markets including
- 13:53Speaker 3: the US? But you know how our biosimilars can continue
- 13:57Speaker 3: to evolve and change, how things impact in terms of
- 14:01Speaker 3: pricing and how pricing is impacted across the board by
- 14:04Speaker 3: the different players. So, and I don't think a lot
- 14:07Speaker 3: of people really fully appreciate the supply chain of product,
- 14:11Speaker 3: you know, how it starts at you know, from manufacturing
- 14:14Speaker 3: to delivery to UH distribution, wholesale down into pharmacy. So
- 14:20Speaker 3: I think there's just a plethora of a topic that
- 14:24Speaker 3: if we're in the industry, we we know, you know,
- 14:27Speaker 3: at least you know, a mile wide and deep, and
- 14:30Speaker 3: we want to dive down in some of those topics
- 14:32Speaker 3: because again, I think the cross conversation between different parties
- 14:38Speaker 3: on this podcast and how it can relate down will
- 14:41Speaker 3: spark uh commentary that will get us thinking broader and
- 14:46Speaker 3: bigger than we are now, because we still have a
- 14:49Speaker 3: tendency to do some things in isolation, I believe, especially
- 14:53Speaker 3: on the manufacturer side, whether it be on the generic
- 14:55Speaker 3: side or the brand side. So there is a there's
- 14:58Speaker 3: a lot of topics, you know, even simple things how
- 15:02Speaker 3: the impact you know, you know, when we think of
- 15:04Speaker 3: the US market, we kind of think of the US
- 15:06Speaker 3: as a whole, but in many respects we are now
- 15:08Speaker 3: fifty little countries. There's a lot of state regulation and
- 15:13Speaker 3: requirements that are very different. Manufacturers have to navigate all
- 15:17Speaker 3: that just to actually provide product in the state. So
- 15:21Speaker 3: that's just one other little example. But I think we
- 15:23Speaker 3: got some really really great topics. As you mentioned, we
- 15:27Speaker 3: really hope people will come and listen and be a
- 15:29Speaker 3: part of this, meaning, as I said, you know, we
- 15:32Speaker 3: have a kind of our kickoff thoughts and what's important,
- 15:34Speaker 3: But ultimately we'd like to drive it because maybe pharmacists
- 15:38Speaker 3: want to hear from us in terms of, you know,
- 15:40Speaker 3: their perspectives on the manufacturing industry and how do we
- 15:43Speaker 3: do this and and what's to come? What's happening changes
- 15:46Speaker 3: at the FDA. Is that going to increase product approvals?
- 15:51Speaker 3: How will the generic landscape continue to evolve, including you know,
- 15:56Speaker 3: more complex products and obviously biosimilars. How does that impact
- 15:59Speaker 3: that ran side vice versa? How does that impact you know,
- 16:03Speaker 3: investment in new development, especially when you think of topics
- 16:06Speaker 3: like rare nor for disease. You know, it's very challenging
- 16:10Speaker 3: to invest a lot of money in a population it's
- 16:13Speaker 3: only twenty thousand patients, and when you have to go
- 16:16Speaker 3: through the same construct of approval. In many cases, there's
- 16:20Speaker 3: always fast track with the FDA. There's different things that
- 16:23Speaker 3: can help you, but at the end of the day,
- 16:24Speaker 3: there's still a lot of burden on the and the
- 16:27Speaker 3: industry at all levels. And I think that's what's important
- 16:30Speaker 3: to share is that you know there's a lot of
- 16:32Speaker 3: burden on the manufacturers, and not to say that you know,
- 16:35Speaker 3: there's always good players and back players all the way
- 16:37Speaker 3: through the system. So whether it's a pharmaceutical company, a pharmacist, physician,
- 16:42Speaker 3: somebody else, there's all stories across the board of people
- 16:45Speaker 3: that have been really good and maybe some people that
- 16:47Speaker 3: have not been as good, or organizations. I've been doing
- 16:51Speaker 3: this for over thirty years, and what's really important to
- 16:53Speaker 3: me is do it better. I want to leave the
- 16:58Speaker 3: footprint of the company I've worked with in the past,
- 17:01Speaker 3: both on the brand because I spent half my career
- 17:03Speaker 3: on the brand side and half my career on the
- 17:06Speaker 3: generic side, so I've been able to really see both
- 17:08Speaker 3: sides of the world. But I think most people in
- 17:11Speaker 3: this business, again, whether you're a provider or whether you're
- 17:14Speaker 3: a manufacturer, for the most part, I think we get
- 17:17Speaker 3: in it because of what I said to you when
- 17:19Speaker 3: I started. When I had a choice to choose from
- 17:21Speaker 3: seven different companies, I choose a company that I felt
- 17:25Speaker 3: that my work would mean something more. And I think
- 17:28Speaker 3: that's what we want to do. So if we can
- 17:29Speaker 3: leave a little unique mark by bringing executives in our
- 17:36Speaker 3: world too closer to pharmacists than other providers to open
- 17:40Speaker 3: up a dialogue on important topics, and from that we
- 17:43Speaker 3: can find solutions. Then now I'll be very happy and
- 17:47Speaker 3: very excited to be a part of what we're trying
- 17:48Speaker 3: to do here.
- 17:49Speaker 2: Excellent. Well, Steve Beckman is Stevens on Lincoln, so you'll
- 17:55Speaker 2: have a link in the show notes that you can
- 18:00Speaker 2: connect with Steven. Also send us a message, as Steven suggested,
- 18:05Speaker 2: if you have ideas for future episodes of The Executive Dose.
- 18:11Speaker 2: And I don't think I'm forgetting anything else. I know
- 18:14Speaker 2: that you're going to be traveling to several conferences. We
- 18:17Speaker 2: hope to meet up with people at national conferences. If
- 18:19Speaker 2: you're going to be present at anything, please reach out
- 18:23Speaker 2: to us. We'll let you know which ones we're actually
- 18:25Speaker 2: going to this year. I know that you and I
- 18:27Speaker 2: are going to be going to an a CDs TSSE
- 18:30Speaker 2: Total Store Expo, and then we'll.
- 18:32Speaker 3: Also be doing HDA and any CDs. These are one
- 18:37Speaker 3: of the things. Although I have the title CEO, I
- 18:40Speaker 3: kind of still think of myself as the director of
- 18:43Speaker 3: Marketing and the director of sales. So I try to
- 18:45Speaker 3: get out to all these meetings as best I can
- 18:50Speaker 3: because I think at the end of the day, you
- 18:51Speaker 3: have to practice what you preach. And if I say
- 18:53Speaker 3: we got to listen. Then I got to make myself
- 18:55Speaker 3: available to listen. Maybe the podcast I'll be doing more
- 18:58Speaker 3: talking than listening, but maybe not. That balances out fifty
- 19:01Speaker 3: to fifty. So we're very, very excited to work with you.
- 19:05Speaker 3: You have built a great network, a great resource to pharmacists.
- 19:10Speaker 3: We couldn't think of a better platform to try to
- 19:13Speaker 3: create something of value, and we will give it our
- 19:16Speaker 3: best shot to do just that.
- 19:18Speaker 2: Thank you so much. Steven Beckman, new host of The
- 19:22Speaker 2: Executive Dose. You heard it here on the Pharmacy Podcast Network.
- 19:26Speaker 2: We thank you so much for listening on all platforms.
- 19:28Speaker 2: Please subscribe Apple, Spotify or anywhere that you listen to podcasts,
- 19:33Speaker 2: and once again let us know how we're doing and
- 19:36Speaker 2: what you'd like to listen to. Appreciate you listening to
- 19:38Speaker 2: the Executive Dose.
- 19:42Speaker 3: Hey, this is Steven Beckman, host of Executive Dose. Come
- 19:46Speaker 3: follow me on LinkedIn. Look forward to hearing from you.